Haisco Pharmaceutical receives exchange acceptance for A-share issuance

Haisco Pharmaceutical Group (SZSE:002653) announced that the Shenzhen Stock Exchange has accepted its application for the issuance of A-shares to specific targets. The decision comes in line with Haisco's 2025 strategic goals to improve its innovation capabilities, expand its drug pipeline, and bolster its market position. The application documents were deemed complete by the exchange. The company seeks to raise capital to fund new drug research initiatives and supplement working capital. While the exchange has accepted the application, the share issuance is subject to further review and registration processes, including final approval from the China Securities Regulatory Commission. Haisco stated that it will comply with continuous information disclosure requirements and advises investors to exercise caution given the uncertainties involved.